COMMUNIQUÉS West-GlobeNewswire

Cancer Genetics Reports Second Quarter 2018 Financial Results and Provides Strategic Business Updates

14/08/2018 - 13:30

Conference call at 8:30 a.m. ET, Tuesday, August 14, 2018 RUTHERFORD, N.J., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic [...]

Stemline Therapeutics to Present at the 2018 Wedbush PacGrow Healthcare Conference

14/08/2018 - 13:30

NEW YORK, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that Ivan Bergstein, M.D., [...]

Nephros Subsidiary Specialty Renal Products and HemoCleanse Announce License Agreement for Dialysate Filtration System

14/08/2018 - 13:30

Pioneering HemoCleanse CEO to Join Specialty Renal Products Board of Directors SOUTH ORANGE, NJ, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Specialty Renal Products, Inc. (SRP), a subsidiary of Nephros, Inc. (OTCQB:NEPH), a [...]

Avalon GloboCare Appoints Dr. James L. Gajewski, Former Medical Director at M.D. Anderson Cancer Center, to Head Scientific and Clinical Advisory Board

14/08/2018 - 13:30

FREEHOLD, N.J., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (OTCQB: AVCO), a leading global developer of cell-based technologies, announced today that the Company has appointed James L. Gajewski, M.D., M.A. [...]

Transactions in relation to share buyback program

14/08/2018 - 13:24

Acting under its share buyback authorization, the GN Store Nord Board of Directors initiated a share buyback program on May 2, 2018, in accordance with article 5 of the regulation (EU) no. 596/2014 of 16 April 2014 on [...]

Optinose Reports Second Quarter 2018 Financial Results and Recent Operational Highlights

14/08/2018 - 13:00

Company reports second quarter net product sales of $1.3 million and that more than 2,600 physicians have prescribed XHANCE since launch Conference call and webcast to be held today at 8:00 a.m. Eastern Time YARDLEY, Pa [...]

Establishment Labs Reports Second Quarter 2018 Financial Results

14/08/2018 - 13:00

NEW YORK, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on improving patient safety and aesthetic outcomes, initially in the breast aesthetics [...]

Microbix Reports Record Third Quarter Sales

14/08/2018 - 13:00

Year-Over-Year Sales Growth of 24% in First Nine Months TORONTO, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, reports financial [...]

UroGen Pharma Reports Second Quarter 2018 Financial Results and Recent Corporate Developments

14/08/2018 - 13:00

Plan to Initiate Q4 2018 Rolling New Drug Application (NDA) Submission to the U.S. Food and Drug Administration (FDA) for UGN-101, Ahead of Initial Projection of Q1 2019 Initiated Phase 2b Clinical Trial of UGN-102 ( [...]

Auxly Announces Product Strategy Update and World-Class Additions to Dosecann's Management Team

14/08/2018 - 13:00

VANCOUVER, British Columbia, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Auxly Cannabis Group Inc. (TSX.V - XLY) (" Auxly " or the " Company ") is pleased to provide an update on the product strategy of the Company’s wholly owned [...]

Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2018

14/08/2018 - 13:00

Second Product Program, NZV930 Enters Clinical Development CAMBRIDGE, Mass., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation [...]

Neuronetics Reports Second Quarter 2018 Financial and Operating Results

14/08/2018 - 13:00

MALVERN, Pa., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life [...]

Athenex, Inc. Announces Second Quarter 2018 Results and Provides Corporate Update

14/08/2018 - 13:00

Second quarter revenue increased to $11.6 million compared to $4.6 million in the same period last year. Received a strategic investment of $100 million from Perceptive Advisors Primary endpoints achieved in two Phase 3 [...]

ReWalk Robotics Reports Second Quarter 2018 Financial Results

14/08/2018 - 13:00

— Total revenue of $1.8 million during the second quarter of 2018 — — VA updates national coverage policy which expands access to ReWalk exoskeletons — YOKNEAM ILIT, Israel and MARLBOROUGH, Mass., Aug. 14, 2018 (GLOBE [...]

Sharps Compliance Reports Fiscal 2018 Fourth Quarter and Year End Results

14/08/2018 - 12:55

Fourth quarter 2018 revenue was $9.9 million with gross margin of 30% and net loss per share of $0.01 Unused Medication solutions business increased 62% Route-based business increased 21% Unused medication management [...]

Eyenovia Reports Second Quarter 2018 Financial Results

14/08/2018 - 12:30

NEW YORK, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver microdosed [...]

HEXO Applauds the Ontario Governments Proposed Retail Framework

14/08/2018 - 12:30

GATINEAU, Quebec, Aug. 14, 2018 (GLOBE NEWSWIRE) -- The Hydropothecary Corporation (“HEXO” or the “Company”) (TSX:HEXO) supports the Ontario government’s announcement that they are planning a consultation for private [...]

HEXO applaudit le cadre de vente au détail proposé par le gouvernement de l’Ontario

14/08/2018 - 12:30

GATINEAU, Québec, 14 août 2018 (GLOBE NEWSWIRE) -- La société Hydropothecary (« HEXO » ou la « Société ») (TSX: HEXO) accueille avec joie l’annonce du gouvernement de l’Ontario concernant son projet de consultation sur [...]

Aptinyx Reports Second Quarter 2018 Financial and Business Results

14/08/2018 - 12:27

Completed upsized initial public offering that raised $117.8 million in gross proceeds EVANSTON, Ill., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing [...]